The CLIP1–LTK fusion is an oncogenic driver in non‐small‐cell lung cancer

IJMS, Free Full-Text

IJMS, Free Full-Text

Frontiers Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

IJMS, Free Full-Text

医药前沿nature发文：CLIP1-LTK 融合基因-非小细胞肺癌的新治疗靶点医药新闻-ByDrug-一站式医药资源共享中心-医药魔方

Frontiers Recent progress in targeted therapy for non-small cell lung cancer

Identification of Ultrasound-Sensitive Prognostic Markers of LAML and Construction of Prognostic Risk Model Based on WGCNA

PDF) Advances in Non-Small Cell Lung Cancer (NSCLC) Treatment—A Paradigm Shift in Oncology

The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. - Abstract - Europe PMC

IJMS, Free Full-Text

Combinatorial tumor suppressor inactivation efficiently initiates lung adenocarcinoma with therapeutic vulnerabilities

IJMS, Free Full-Text

Frontiers Recent progress in targeted therapy for non-small cell lung cancer

Clinical application of the AMOY 9-in-1 panel to lung cancer patients - ScienceDirect